Stock listing

Euronext:ADOC Adocia SA Action

Home listing (Euronext) of Adocia SA

Follow Adocia SA into a list and get an email when it puts out news.

Share price · EURONEXT:ADOC

€3.29 EUR -0.24 (-6.7%)

Close on Nov 20, 2026

Past year -58.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€3.26 – €3.49 EURNov 20, 2026
Volume
311,387 sharesNov 20, 2026
Market cap
€72.26M EURAt the close on Nov 20, 2026 · price × 21.94M shares outstanding
52-week range
€2.01 – €8.61 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€1.11M EURMedian day 133,417 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Adocia SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:ADOC · Home€3.294 EUR-0.238 (-6.7%)311,387€3.46€3.492€3.258€3.532Close on Nov 20, 2026
LSE:0QAI€3.36 EUR-0.316 (-8.6%)736€3.47€3.47€3.36€3.676Close on Nov 20, 2026
Frankfurt:A89€3.36 EUR-0.17 (-4.8%)—€3.36€3.36€3.36€3.53Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ADOC · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€3.294-0.238-6.7%€3.46€3.492€3.258311,387
€3.532-0.26-6.9%€3.92€3.95€3.51603,126
€3.792-0.428-10.1%€4.064€4.064€3.764684,987
€4.22-0.454-9.7%€4.698€4.76€4.22998,508
€4.674+0.37+8.6%€4.20€5.20€4.151,781,701
€4.304-0.076-1.7%€4.40€4.576€4.10927,933
€4.38+0.58+15.3%€3.852€4.60€3.8042,007,148
€3.80+0.76+25.0%€3.12€3.98€3.121,627,757
€3.04+0.288+10.5%€2.752€3.04€2.726218,432
€2.752-0.09-3.2%€2.828€2.828€2.746106,872
€2.842+0.014+0.5%€2.844€2.946€2.782164,749
€2.828-0.102-3.5%€2.92€2.972€2.752313,512
€2.93-0.19-6.1%€3.10€3.10€2.822492,634
€3.12+0.092+3.0%€2.902€3.338€2.86435,323
€3.028-0.032-1.0%€3.30€3.384€3.028834,037
€3.06-0.062-2.0%€3.238€3.45€3.026627,281
€3.122+0.408+15.0%€2.82€3.34€2.788993,457
€2.714+0.258+10.5%€2.46€2.714€2.432313,953
€2.456+0.058+2.4%€2.38€2.55€2.318211,529
€2.398-0.032-1.3%€2.428€2.48€2.37890,889
€2.43+0.07+3.0%€2.34€2.442€2.324167,515
€2.36-0.086-3.5%€2.468€2.60€2.34438,047
€2.446+0.174+7.7%€2.24€2.464€2.148526,384
€2.272-0.038-1.6%€2.232€2.30€2.22139,089
€2.31-0.26-10.1%€2.60€2.60€2.282619,637
€2.57+0.40+18.4%€2.204€2.62€2.194503,601
€2.17+0.15+7.4%€2.068€2.17€2.024130,842
€2.02-0.068-3.3%€2.09€2.13€2.0290,581
€2.088+0.034+1.7%€2.07€2.09€2.02103,879
€2.054+0.044+2.2%€2.04€2.178€2.034167,363
€2.01-0.056-2.7%€2.08€2.094€2.0195,506
€2.066-0.034-1.6%€2.12€2.12€2.0599,663
€2.10-0.03-1.4%€2.16€2.22€2.08113,144
€2.13-0.016-0.7%€2.148€2.25€2.126139,889
€2.146-0.104-4.6%€2.25€2.302€2.11298,083
€2.25-0.22-8.9%€2.51€2.53€2.19476,037
€2.47-0.206-7.7%€2.678€2.678€2.412412,895
€2.676+0.048+1.8%€2.654€2.83€2.634253,113
€2.628+0.008+0.3%€2.63€2.686€2.546306,349
€2.62-0.87-24.9%€3.12€3.12€2.5341,064,685
€3.49-0.044-1.2%€3.50€3.55€3.4844,766
€3.534-0.076-2.1%€3.61€3.678€3.53462,058
€3.61+0.028+0.8%€3.592€3.61€3.5262,153
€3.582-0.068-1.9%€3.65€3.65€3.55440,938
€3.65-0.018-0.5%€3.66€3.79€3.6442,096
€3.668+0.064+1.8%€3.61€3.70€3.59446,136
€3.604-0.06-1.6%€3.668€3.668€3.59867,707
€3.664+0.118+3.3%€3.54€3.778€3.5292,543
€3.546-0.102-2.8%€3.628€3.628€3.474104,821
€3.648-0.152-4.0%€3.774€3.774€3.62127,275
€3.80-0.08-2.1%€3.90€3.954€3.76485,178
€3.88-0.052-1.3%€3.95€3.96€3.8830,692
€3.932-0.024-0.6%€3.952€3.952€3.8880,528
€3.956-0.044-1.1%€4.00€4.00€3.9251,512
€4.00-0.128-3.1%€4.12€4.12€4.0037,883
€4.128+0.004+0.1%€4.12€4.13€4.0271,464
€4.124+0.106+2.6%€4.02€4.17€3.98112,895
€4.018+0.03+0.8%€4.00€4.018€3.9255,333
€3.988-0.008-0.2%€3.994€4.02€3.9646,017
€3.996-0.016-0.4%€4.02€4.068€3.99631,732
€4.012+0.032+0.8%€4.00€4.05€3.9837,398
€3.98-0.03-0.7%€4.00€4.09€3.95690,232
€4.01-0.05-1.2%€4.06€4.10€3.94135,991
€4.06-0.11-2.6%€4.14€4.14€4.00112,351
€4.17+0.048+1.2%€4.12€4.184€4.06474,576
€4.122-0.112-2.6%€4.25€4.27€4.102109,533
Ticker
Euronext:ADOC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Euronext
Currency
EUR

What changed lately

Latest news

All Adocia SA news

Adocia SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 39 in all · newest Nov 16, 2026 · oldest 2025
Decks
49 decks · latest Nov 2, 2026

Where Adocia SA is listed

ListingExchangeCountryCurrency
Euronext:ADOC · Home listing · This pageEuronextFranceEUR
LSE:0QAILSEUnited KingdomEUR
LS Exchange:A1JTC2LS ExchangeGermanyEUR
gettex:A89gettexGermanyEUR
Tradegate:A89TradegateGermanyEUR
Lang & Schwarz:A1JTC2Lang & SchwarzGermanyEUR
OTC:ADOCYOTCUnited StatesUSD
Aquis:ADOCPAquisUnited KingdomEUR
Aquis:ADOCPAquisUnited KingdomEUR
Dusseldorf:A89DusseldorfGermanyEUR
Frankfurt:A89FrankfurtGermanyEUR
Hamburg:A89HamburgGermanyEUR
Munich:A89MunichGermanyEUR
Stuttgart:A89StuttgartGermanyEUR
Turquoise:ADOCPTurquoiseUnited KingdomEUR

Valuation

EV/sales 48.1× against a median of 5.4×: 5th lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€70.92M EUR
P/E
Loss
EV/sales
48.1×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Adocia SA · EURONEXT:ADOCUS$79.30MUS$77.84Mn/a48.1×n/an/an/an/an/a
TuHURA Biosciences, Inc. · NASDAQ:HURAUS$82.20MUS$89.50Mn/an/an/a4.3×n/a0.5×2.81
3D Medicines, Inc. · HKEX:1244US$81.88MUS$48.38Mn/a0.9×n/a1.0×−49.9%0.3×n/a
Kintor Pharmaceutical Ltd · HKEX:9939US$81.71MUS$96.98Mn/a19.8×n/a5.0×−612.3%1.2×n/a
Nkarta, Inc. · NASDAQ:NKTXUS$81.38M−US$75.22Mn/an/an/a0.4×n/a0.0×1.67
Captor Therapeutics SA · GPW:CTXUS$81.12MUS$64.16Mn/a130×n/a5.1×n/a0.0×n/a
Vaxart, Inc. · OTC:VXRTUS$79.89MUS$14.34M2.8×0.1×0.4×1.2×16.0%0.0×1.21
Sensorion SAS · EURONEXT:ALSENUS$79.63M−US$13.98Mn/an/an/a0.9×n/a0.0×n/a
Tiziana Life Sciences Ltd · NASDAQ:TLSAUS$78.98MUS$76.73Mn/an/an/an/an/an/a1.23
Nyrada, Inc. · ASX:NYRUS$78.76MUS$73.21Mn/an/an/a12.5×n/a0.0×n/a
TiumBio Co., Ltd. · KRX:321550US$76.77MUS$60.20Mn/a5.4×n/a2.9×−114.1%0.3×n/a
Median of the othersUS$80.50MUS$62.18M2.8×5.4×0.4×2.9×−82.0%0.0×1.45

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
9.45 EUR · Analysts' mean
EPS, year to Dec 2026
0.51 · 2 analysts
Revenue, year to Dec 2026
28.39M · 2 analysts

Team and board

Officers

OfficerRole
Olivier SoulaChief Executive Officer
Mathieu-William GilbertChief Financial Officer - Chief Operating Officer
Alexander Zan FlemingPresident
David RigalPharmaceutical Operations Director
Géraldine Favre SoulaDirector of human resources

Board

DirectorRole
Stéphane BoisselChairman of the Board
Tim HeiseChairman of the Board of Directors
Jacky VonderscherBoard member
Mads DallBoard member
Maureen DeehanBoard member
Olivier SoulaChief Executive Officer
Valérie MoumdjianBoard member

Events

QuarterResultsShare move
Q4 2025Feb 24, 2026−1.8%
Quarter to Sep 30, 2025Oct 15, 2025−0.4%
Q2 2025Sep 29, 2025+11.2%
Quarter to Mar 31, 2025Apr 30, 2025+4.8%
Quarter to Sep 30, 2024Oct 30, 2024−4.6%
Q2 2024Sep 19, 2024−0.5%
Quarter to Mar 31, 2024Apr 24, 2024 · After close−7.8%
Q3 2023Oct 25, 2023 · After close+3.4%
Q2 2023Sep 18, 2023 · After close−20.5%
Q1 2023Apr 25, 2023 · After close−1.8%
All 18 quarters
QuarterResultsShare move
Q4 2022Mar 15, 2023 · After close−4.1%
Q3 2022Oct 25, 2022 · After close+1.8%
Q2 2022Sep 20, 2022 · After close−8.7%
Q1 2022Apr 26, 2022 · After close−1.0%
Q3 2021Oct 26, 2021+1.8%
Q2 2021Sep 7, 2021−1.3%
Q1 2021Apr 21, 2021−3.7%
Q4 2020Mar 18, 2021−4.5%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings19 slidesNov 2, 2026
Investor Presentation (November 2026)Investor deck33 slidesNovember 2026
Investor Presentation (June 2026)Investor deck43 slidesJune 2026
Investor Presentation (March 2026)Investor deck43 slidesMarch 2026
Investor Presentation (November 2025)Investor deck42 slidesNovember 2025
Shareholder Meeting (June 2025)Shareholder meeting85 slidesJun 11, 2025
Investor Presentation (April 2025)Investor deck30 slidesApr 1, 2025
Investor Presentation (February 2025)Investor deck30 slidesFeb 18, 2025
Investor Presentation (January 2025)Investor deck30 slidesJanuary 2025
Investir Day 2024Conference11 slidesNovember 2024
All 49 decks
DeckKindSlidesDate
Investor Presentation (September 2024)Investor deck41 slidesSeptember 2024
Shareholder Meeting (June 2024)Shareholder meeting94 slidesJun 13, 2024
Investor Presentation (April 2024)Investor deck42 slidesApril 2024
Investor Presentation (April 2024)Investor deck42 slidesApril 2024
Investor Presentation (April 2024)Investor deck18 slidesApril 2024
Investor Presentation (March 2024)Investor deck42 slidesMarch 2024
Investor Presentation (March 2024)Investor deck42 slidesMarch 2024
Investor Presentation (January 2024)Investor deck23 slidesJanuary 2024
LSX Investival (November 2023)Conference23 slidesNovember 2023
Investor Presentation (October 2023)Investor deck42 slidesOctober 2023
Investor Presentation (October 2023)Investor deck42 slidesOctober 2023
Shareholder Meeting (May 2023)Shareholder meeting81 slidesMay 11, 2023
Investor Presentation (March 2023)Investor deck48 slidesMarch 2023
Investor Presentation (January 2023)Investor deck48 slidesJanuary 2023
Investor Presentation (January 2023)Investor deck48 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck49 slidesNovember 2022
Investor Presentation (November 2022)Investor deck49 slidesNovember 2022
Shareholder Meeting (June 2022)Shareholder meeting71 slidesJun 15, 2022
Investor Presentation (May 2022)Investor deck43 slidesMay 2022
Investor Presentation (April 2022)Investor deck38 slidesApril 2022
Investor Presentation (January 2022)Investor deck37 slidesJanuary 2022
Investor Presentation (January 2022)Investor deck39 slidesJanuary 2022
Investor Presentation (October 2021)Investor deck40 slidesOctober 2021
Investor Presentation (June 2021)Investor deck40 slidesJune 2021
Shareholder Meeting (May 2021)Shareholder meeting65 slidesMay 20, 2021
Shareholder Meeting (May 2021)Shareholder meeting65 slidesMay 20, 2021
Investor Presentation (September 2020)Investor deck28 slidesSeptember 2020
Investor Presentation (January 2020)Investor deck32 slidesJanuary 2020
Shareholder Meeting (May 2019)Shareholder meeting73 slidesMay 16, 2019
Investor Presentation (April 2019)Investor deck36 slidesApril 2019
Investor Presentation (September 2018)Investor deck36 slidesSeptember 2018
Investor Presentation (June 2018)Investor deck35 slidesJune 2018
Shareholder Meeting (May 2018)Shareholder meeting60 slidesMay 17, 2018
Investor Presentation (May 2018)Investor deck40 slidesMay 2018
Investor Presentation (April 2018)Investor deck39 slidesApril 2018
Investor Presentation (January 2018)Investor deck40 slidesJanuary 2018
Investor Presentation (September 2017)Investor deck35 slidesSeptember 2017
Investor Presentation (June 2017)Investor deck32 slidesJune 2017
Investor Presentation (April 2012)Investor deck56 slidesApril 2012

Open Decks

Financings

RaiseDateIn US dollars
New shares under shareholder loan agreement
Tranche closed: convertible
Buyers: Vester Finance (shareholder loan of up to €10 million)
Nov 6, 2026
Private placement of new ordinary shares
Announced: €3M · €2.042 a share · Vester Finance
Dealers: Vester Finance
Buyers: Olivier Soula (2% of the Company’s share capital following completion of the Capital Increase); Vester Finance (6.9% of the Company’s share capital following completion of the Capital Increase)
Insiders: All the directors of the Company, including the chief executive officer, participated in the Capital Increase
Use of proceeds: Promote BioChaperone technology to sign partnerships, develop AdoXLong platform towards clinic, and general corporate purposes
Oct 20, 2026US$3.36M
New shares
Tranche closed: raise
Buyers: Vester Finance (200,000 new shares issued over the month under the shareholder loan agreement)
Aug 24, 2026
Shareholder loan repayable in new shares
Update: up to €6M
Buyers: Vester Finance (shareholder loan of up to €6.0 million)
Use of proceeds: Extend cash runway until the beginning of Q2 2027
Apr 21, 2026US$7.05M
Private placement of new ordinary shares with share warrants attached (ABSAs)
Closed: €10M raised · €7.92 a share · Warrants at €9.11 for 42 months · Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (Stifel)
Dealers: Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (Stifel) (lead)
Buyers: CVI Investments, Inc. (subscribed the whole €10 million; 1,262,626 shares, 6.5% of capital post-offering)
Use of proceeds: About 50% for the AdoXLong platform, 30% for BioChaperone industrial-scale manufacturing, 20% for working capital
Dec 4, 2025US$11.66M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.48M9.32M2.15M11.4M1.44M841.0K2.14M47.4M19.5M22.5M
Cost of revenue19.4M19.1M765.0K1.84M1.26M1.46M1.71M2.19M1.74M1.78M
Gross profit-17.9M-9.83M1.39M9.61M180.0K-616.0K437.0K45.2M17.7M20.7M
Research and development14.2M14.5M14.8M25.9M20.0M22.5M23.3M25.8M27.1M30.4M
Selling, general and administrative9.61M5.48M240.0K265.0K257.0K13.1M25.6M19.0M19.1M
Operating income-15.8M-7.40M-14.2M-1.70M-19.4M-21.1M-22.0M9.71M-42.5M-8.00M
Depreciation and amortization601.0K654.0K508.0K496.0K1.16M1.20M1.16M1.04M1.01M740.0K
EBITDA-15.2M-6.75M-13.7M-1.20M-18.2M-19.9M-20.9M10.8M-41.5M-7.26M
Interest expense841.0K1.01M7.00M5.30M3.61M2.07M416.0K149.0K110.0K78.0K
Income before tax-16.6M-8.37M-21.2M-6.42M-22.8M-23.3M-21.6M11.8M-8.52M-7.82M
Income tax-12.0K952.0K2.00K476.0K029.0K-2.96M4.14M35.0K72.0K
Net income-16.6M-9.32M-21.2M-6.90M-22.8M-23.3M-18.6M7.62M-8.55M-7.89M
Earnings per share, basic-0.90-0.60-1.90-0.90-3.20-3.34-2.681.00-1.25-1.15
Earnings per share, diluted-0.90-0.60-1.90-0.90-3.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents17.3M7.53M13.0M17.4M15.2M28.1M43.7M39.8M34.8M58.0M
Short-term investments-1.00K-1.00K-1.00K-1.00K
Receivables145.0K8.60M111.0K467.0K207.0K6.61M7.01M12.2M328.0K11.4M
Inventory362.0K220.0K132.0K137.0K517.0K569.0K181.0K131.0K99.0K66.0K
Current assets23.9M22.4M20.2M26.3M22.1M36.4M52.2M61.0M44.7M70.0M
Property, plant and equipment3.12M3.17M2.85M967.0K8.53M9.54M8.73M8.97M8.45M
Goodwill00
Total assets28.5M27.0M25.0M30.6M30.1M45.2M62.0M70.0M53.8M78.8M
Accounts payable2.84M3.53M3.97M6.41M3.83M2.43M2.65M3.66M1.62M1.74M
Current liabilities20.0M20.9M19.8M25.1M23.8M10.7M11.2M14.9M8.88M28.0M
Long-term debt01.95M4.54M17.5M18.3M25.2M18.5M4.89M5.78M6.28M
Total debt8.90M11.8M13.1M33.2M34.5M28.2M21.2M7.12M7.57M7.07M
Total liabilities27.0M30.1M31.9M43.6M43.9M38.8M33.9M24.2M16.9M36.0M
Shareholders' equity1.49M-3.09M-6.91M-13.0M-13.8M6.33M28.0M45.8M36.9M42.8M
Shares outstanding19.6M15.7M14.1M8.73M7.27B6.97M6.94M7.62M6.86M6.85M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.53M-15.6M-4.95M-15.0M-19.2M-21.9M-9.65M6.31M-22.2M-13.1M
Capital spending-267.0K-229.0K-156.0K-153.0K-361.0K-205.0K-2.02M-784.0K-1.98M-8.08M
Free cash flow-6.80M-15.8M-5.11M-15.1M-19.6M-22.1M-11.7M5.53M-24.2M-21.2M
Cash from investing-275.0K-258.0K-138.0K21.9M-361.0K-204.0K-2.05M-1.03M-1.69M-7.19M
Cash from financing16.5M10.4M629.0K-4.61M6.64M6.51M15.5M-216.0K653.0K6.30M
Share buybacks12.1M7.87M01.04M002.00K40.0K4.00K
Change in cash9.72M-5.43M-4.46M2.26M-13.0M-15.5M3.82M5.06M-23.3M-14.0M

Open Financials

Cap table

Built by 6ix from Adocia SA’s releases · as of Nov 6, 2026

Common shares
21,937,614
Fully diluted
21,937,614

Fully diluted

LineSharesAs of
Common shares21,937,614Aug 24, 2026

Warrants and options

Lot
Warrants · €9.11 · expire about Jun 2029

Share count over time

CountShares
Aug 24, 202621,937,614

Open Cap table

Shareholders

StakeStakeSharesDateFiling
de droit suisse Vester Finance6.61%1.45MOct 22, 2026AMF threshold crossing notice

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alexander Zan FlemingPresident · Since at least Nov 4, 2026
Dan EinhornSince at least Nov 4, 2026
David RigalPharmaceutical Operations Director · Since at least Nov 5, 2026
Ekaterina SmirnyaginaDirector · Until Sep 1, 2026 · Past
Géraldine Favre SoulaDirector of human resources · Since at least Nov 5, 2026
Jacky VonderscherBoard member · Since at least Sep 24, 2026
Mads DallBoard member · Since at least Nov 5, 2026
Mathieu-William GilbertChief Financial Officer - Chief Operating Officer · Since at least Oct 29, 2026
Maureen DeehanBoard member · Since at least Oct 29, 2026
Olivier SoulaChief Executive Officer · Since at least Oct 29, 2026
All 13 people
PersonSeat
Stéphane BoisselChairman of the Board · Since at least Oct 20, 2026
Tim HeiseChairman of the Board of Directors · Since at least Sep 24, 2026
Valérie MoumdjianBoard member · Since at least Sep 25, 2025

Open People

Log in to ask 6ix AI your own questions about Adocia SA.